Navigation Links
Making personalized lung cancer therapy a reality in Europe
Date:4/30/2010

The recent approval of Europe's first personalized treatment for lung cancer heralds the arrival of a new era for lung cancer treatment that will demand significant changes to the way cancer specialists and other hospital doctors work, a leading expert said today at the 2nd European Lung Cancer Conference in Geneva, Switzerland.

Prof Robert Pirker of the Medical University of Vienna said that personalized therapy, in which treatment is based on the characteristics of an individual patient's tumor, promised to improve outcomes for patients, as well as being more cost-effective and less toxic than existing treatments.

"Recently, oral treatment with the targeted drug gefitinib was shown to be superior with regard to progression-free survival compared to treatment with up to six cycles of first-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) who have mutations in their tumors that activate a cell-surface molecule called epidermal growth factor receptor (EGFR)," Prof Pirker said.

This finding led to the approval of this drug in Europe in 2009 --but only for treating patients whose tumors carry these mutations.

"Before we can offer patients gefitinib, the presence of these mutations in tumor cells has to be clearly demonstrated," he explained.

In order to achieve this, doctors must perform a molecular analysis of tumor material from biopsies. "This will benefit patients, but it changes the whole diagnostic workup and requires some change in the thinking of oncologists, including closer co-operation between the various disciplines: interventional pulmonologists, pathologists, biologists, oncologists," he said.

Scientists around the globe are currently probing the genetics of cancers with the aim of identifying new targets for personalized treatment. These projects, such as the International Cancer Genome Consortium, mean that testing for mutations in tumors will become routine.


'/>"/>
Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2

Related biology news :

1. Making its predators tremble: Multiple defenses act synergistically in aspen
2. National Honor to History-Making Undersea Explorer
3. Making the blind see: Gene therapy restores vision in mice
4. The formula for making teeth will soon be found
5. Texas Childrens discharges history-making patient
6. Making the case for the social sciences
7. Scientists hope to end sleeping sickness by making parasite that causes it self-destruct
8. To a mosquito, matchmaking means singing in perfect harmony
9. Bacteria provide new insights into human decision making
10. Physical education teaching staff play key role in making you like sport
11. A major step in making better stem cells from adult tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2014)... 2014 -- Using corn crop residue to make ethanol ... more greenhouse gases than gasoline, according to a study ... . , The findings by a University of Nebraska-Lincoln ... can be used to meet federal mandates to ramp ... Corn stover -- the stalks, leaves and cobs in ...
(Date:4/18/2014)... researchers have published soil organic carbon sequestration rates. ... organic carbon can be sequestered by simply switching from ... there is a growing body of research with evidence ... cover crops, small grains, and forages may not be ... , "Some studies have shown that both moldboard and ...
(Date:4/18/2014)... team of researchers led by a University of California, ... a $7.5 million Department of Defense grant to uncover ... foundations for the predictable design of light-weight, tough and ... structures from plants and animals, including the mantis shrimp, ... systems have constructed over millions of years and coming ...
Breaking Biology News(10 mins):Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3Researchers question published no-till soil organic carbon sequestration rates 2Researchers question published no-till soil organic carbon sequestration rates 3Researchers question published no-till soil organic carbon sequestration rates 4Mantis shrimp, toucan and trilobite, oh my 2Mantis shrimp, toucan and trilobite, oh my 3
... in the June issue of American Naturalist, Erika J. ... and Michael J. Donoghue (Yale University) explore how leafy, ... "The cactus form is often heralded as a striking ... in plants," write the authors. "A succulent, long-lived photosynthetic ...
... researcher in Washington, D.C., has been working toward tracking ... hepatitis C. , Dr. Maria Sjogren, a retired Army ... in treating liver disease, has enrolled 90 active-duty servicemembers ... Center. The virus, which affects the U.S. military at ...
... Max Planck scientists have identified a new strategy which ... was carried out by Prof. Jonathon Howard and Stefan ... Biology and Genetics in Dresden. The motor protein MCAK ... end of microtubules where it disassembles them. This is ...
Cached Biology News:Researcher studies, treats military with 'silent disease' 2Researcher studies, treats military with 'silent disease' 3Researcher studies, treats military with 'silent disease' 4
(Date:1/15/2014)... DTS Language Services, Inc . is pleased to announce ... organizations who need document translations. Clients will now have ... in advance with a selection of nearly 50 life science ... critical factor in clinical and scientific fields, and decrease the ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a ... innovative therapies addressing major unmet medical needs using ... Notice of Allowance from the United States Patent ... compounds (sd-rxRNA®), for the treatment of fibrosis. The ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... cells, called photoreceptors, could hold the key to stopping ... diseases, Yale School of Medicine researchers report in the ... Several blinding disorders are known to cause ... comparative medicine and ophthalmology at Yale School of Medicine, ...
... , PHOENIX, Nov. 16 NutraCea (OTC: ... research and technology, announced today that Henk Hoogenkamp, a world ... meat processing industries, has agreed to act as an Executive ... results of research and development in various applications to further ...
... , BOSTON, Nov. 16 Hollis-Eden Pharmaceuticals, ... of its ongoing Phase I/II clinical trial with Apoptone® ... cancer or CRPC). Presented at the Molecular ... the AACR, NCI and EORTC, the poster is titled: ...
Cached Biology Technology:Finding a protective mechanism for retinal cells could save sight 2Henk Hoogenkamp, Accomplished Author and Food Ingredient Scientist, Joins NutraCea as Executive Advisor on the Utilization of Stabilized Rice Bran in Food Ingredient Applications 2Henk Hoogenkamp, Accomplished Author and Food Ingredient Scientist, Joins NutraCea as Executive Advisor on the Utilization of Stabilized Rice Bran in Food Ingredient Applications 3Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference 2Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference 3Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference 4
... Idaho Technologys R.A.P.I.D. System (Ruggedized Advanced ... real-time, PCR thermocycler designed for field ... environments. In addition to its ruggedness, ... sensitivity and specify as the LightCycler ...
... ES Cell Characterization Kit consists of two ... as well as four ES cell-specific antibodies ... • Stem cells have become the subject ... their therapeutic potential and because they raise ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
... Note: Evaluated for its amino acid acceptor activity ... acids Ala, Asp, Gly, Ile, Lys, Pro, Thr, ... Preparation Unit Definition: One unit will yield an ... of water (1 cm light path). ...
Biology Products: